Blind 2Stage [Two-Stage / GS Designs]

posted by Astea – Russia, 2019-05-30 10:37  – Posting: # 20305
Views: 1,217

Dear Smart People!

Digging forum posts I've found this 9-year old question from Detlew. It turns out that the question can be now easily answered by the author after constructing Power2Stage.
But can you clarify me the meaning of blindness in BE trials?

I naively thought that blind interim analyses should not influence the type-one error. But
comparing power.tsd.ssr(n1=10,CV=0.1,blind=FALSE,theta0=1.25) and power.tsd.ssr(n1=10,CV=0.1,blind=TRUE,theta0=1.25) it turns out that blinding may even worse the situation (5.01% vs 7.36%, TIE). It is connected with the unknown PE (cause for BLIND=TRUE s20s<-mses), but isn't it contrintuitive?

Can it be true for parallel design also? Suppose we want to make a blind interim analyses after first stage with N subjects and recalculate sample size on fixed GMR=0.95 if total CV would be greater than initial suggestion. Will it cause any inflation? How to estimate it?

"We are such stuff as dreams are made on, and our little life, is rounded with a sleep"

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,545 posts in 4,145 threads, 1,340 registered users;
online 5 (0 registered, 5 guests [including 3 identified bots]).
Forum time (Europe/Vienna): 12:12 CEST

Anyone who has never made a mistake
has never tried anything new.    Albert Einstein

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5